<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab (BV) is an antivascular endothelial growth factor antibody </plain></SENT>
<SENT sid="1" pm="."><plain>When administered with other chemotherapeutic drugs, BV-combined regimens prolong survival of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a phase II trial to confirm the pharmacokinetic parameters from 3-Tesla dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as surrogate biomarkers of BV + FOLFIRI regimen efficacy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DCE-MRI was performed before treatment, on the seventh day after first treatment and every 8 weeks thereafter using a 3-Tesla MRI system </plain></SENT>
<SENT sid="4" pm="."><plain>DCE-MRI parameters-area under the contrast concentration versus time curve at 90 and 180 s (AUC90 and AUC180, respectively) after contrast injection, and volume transfer constant of contrast agents (K(trans) and K(ep) ) were calculated from <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Fifty-eight <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>Univariate analysis revealed that a decrease in K(trans) ratios (ΔK(trans) ), K(ep) ratios (ΔK(ep) ), AUC90 ratios (ΔAUC90) and AUC180 ratios (ΔAUC180) correlated with higher response (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001) and longer time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) (ΔK(trans) : p = 0.001; ΔK(ep) : p = 0.004; ΔAUC90: p = 0.006; ΔAUC180: p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analysis showed that ΔAUC180 was correlated with higher response (p = 0.009), and ΔK(trans) and ΔAUC180 were correlated with longer <z:chebi fb="1" ids="18284">TTP</z:chebi> (ΔK(trans) : p = 0.001; ΔAUC180: p = 0.024). ΔK(trans) and ΔAUC180 are pharmacodynamic biomarkers of the blood perfusion of BV + FOLFIRI </plain></SENT>
<SENT sid="8" pm="."><plain>Our data suggest that ΔK(trans) and ΔK(ep) can predict response to chemotherapy at 1 week </plain></SENT>
<SENT sid="9" pm="."><plain>Changes in 3-Tesla DCE-MRI parameters confirmed the potential of these biomarkers of blood perfusion as surrogate predictors of response and <z:chebi fb="1" ids="18284">TTP</z:chebi> </plain></SENT>
</text></document>